Quince Therapeutics, Inc.

NASDAQ: QNCX · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001662774Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 23DQ —GM —SS 42

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, workforce scale · ↓ Piotroski F, balance-sheet leverage

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$84.0M

Employees

as of 2026-09-21

Market cap

$8.1M

as of 2026-09-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$84.0M-$84.0M2025

Operating income-$58.1M-$58.1M2025

Total assets$93.5M$93.5M2025

Liabilities$129.2M$129.2M2025

Equity-$35.7M-$35.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Quince Therapeutics, Inc.’s financial profile?

Quince Therapeutics, Inc. earned -$84.0M in FY2025 net income.

Peers · Healthcare

Conavi Medical Corp.——Aprea Therapeutics, Inc.——Advanced Biomed Inc. Common Stock——Skye Bioscience, Inc.——CNS Pharmaceuticals, Inc.——Apimeds Pharmaceuticals US, Inc——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B74B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEODirk Thye

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: QNCX

Employees38

IPO date2019-05-09

Latest filings

8-K2026-09-04 8-K2026-08-27 DEF 14A2026-08-25 8-K2026-08-17 10-Q2026-08-14 8-K2026-08-14 8-K2026-07-31 8-K2026-06-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.